undamentalytics Newsletter
Sign in

Altimmune, Inc. income statement

In fiscal 2025, Altimmune, Inc. reported revenue of $41,000, up 105.0% on the year before, operating income of −$94.5m (a -230461.0% margin) and net income of −$88.1m, or −$1.00 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue212431110684−0000
Research and development21217181818507571668266
General and administrative181478109131517182128
Operating income−24−12−11−52−43−21−55−97−88−96−103−94
Interest expense600000000002
Net interest income——0—————————
Income before tax−35−4−11−52−45−21−54−97−85−88−95−89
Income tax——0−6−6−0−5—−0——−1
Net income−35−4−11−46−39−21−49−97−85−88−95−88
Diluted EPS−$81.00−$0.20$7.38−$59.45−$7.58−$0.80−$1.91−$2.35−$1.81−$1.66−$1.34−$1.00
Diluted shares (average)————6m26m26m41m47m53m71m88m
EBITDA−23−11−11−52−43−21−54−96−88−95−103−94

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ALT vs LYELAIM vs ALTALT vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Altimmune, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Altimmune, Inc.